Skip to main content

Table 2 Major adverse events associated with lenvatinib

From: Optimal use of lenvatinib in the treatment of advanced thyroid cancer

  

Hypertension

Diarrhea

Fatigue

PPE

Proteinuria

Thrombocytopenia

Phase III (general population) (n = 261) [2]

Any grade

68

59

59

32

31

9

Grade ≥ 3

42

8

9

3

10

2

Phase III (Japanese population) (n = 30) [7]

Any grade

87

60

60

70

63

47

Grade ≥ 3

80

0

13

3

20

7

  1. Events are listed in order of the most frequent events of any grade in the general population
  2. Data are shown as incidence (%). PPE, palmar–plantar erythrodysesthesia